1. Scrip
  2. >>Therapy Areas

Bristol Lays Groundwork For First Dermatology Launch, Ahead Of TYK2 Inhibitor

The Company Will Begin Hiring A Sales Force

 
• By Jessica Merrill

The company has not even filed the TYK2 inhibitor deucravacitinib for psoriasis, but Bristol will be a new player in a category dominated by entrenched rivals.

Team building
Bristol is laying the foundation for a new launch • Source: Alamy

Bristol Myers Squibb Company is already laying the commercial groundwork for the launch of its potential first-in-class TYK2 inhibitor deucravacitinib for psoriasis even though a US approval is at least a year away. The company said it will begin hiring a sales force in the second half of the year as it plans to make a blockbuster-sized splash into a new therapy area dominated by experienced rivals. The company has already established a medical team experienced in dermatology.

"This is a new area for BMS, and thus we've been engaged in a significant capability build to ensure that we have the right team on board," chief commercial officer Christopher Boerner said during a virtual presentation concurrent with the American Academy of Dermatology meeting on 23 April

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Immunological

More from Therapy Areas

Copycats Compound Novo’s Wegovy Growth Problems

 
• By Andrew McConaghie

The US FDA has ordered compounders of the Danish firm's obesity drug semaglutide to shut up shop later this month, but competition from Eli Lilly is only increasing.

First Win For AstraZeneca’s Enhertu In Early-Stage Breast Cancer Treatment

 
• By Andrew McConaghie

Already dominating in later lines of breast cancer treatment, Enhertu could now displace both chemotherapy combinations and Roche’s Kadcyla in early-stage HER2-positive patients.

In Brief: Strong OS Results For Immutep’s Eftilagimod/Keytruda Combo In Head And Neck Cancer

 
• By Sushmita Panda

Australian firm's combo of eftilagimod and Keytruda shows 17.6-month median overall survival in first-line HNSCC patients with low PD-L1, raising hopes for potential accelerated approval.